Rubius Therapeutics Presents Updated Data From Its Type 1 Diabetes Preclinical Program in… | New

Prevention of type 1 diabetes in a rigorous preclinical model from an ongoing experiment;

Two antigens prevent disease caused by many self-antigens demonstrating control suppression

Findings Potentially Translatable to Multiple T-Cell Mediated Autoimmune Diseases

CAMBRIDGE, Mass., June 22, 2022 (GLOBE NEWSWIRE) — Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that biologically modifies red blood cells to create an entirely new class of cell-based drugs called Red Cell Therapeutics ™ for the treatment of cancer and autoimmune diseases, today announced updated preclinical data for its type 1 diabetes program at the 2022 FOCIS Annual Meeting in San Francisco, Calif., June 21-24 2022.

“We believe that these new preclinical data, which are part of an ongoing experiment, demonstrate diabetes prevention and control suppression in the preclinical model of nonobese diabetes, or NOD, the primary model used to study autodiabetes. -immune disease that bears striking similarities to human disease,” said Larry Turka, MD, Chief Scientific Officer and Head of Research and Translational Medicine, Rubius Therapeutics. “We believe these findings extend to our other programs autoimmune disease preclinical studies in celiac disease and multiple sclerosis. We expect to select a clinical candidate for our type 1 diabetes program later this year.”

Induction of antigen-specific immune tolerance in type 1 diabetes by antigen-expressing Re cell therapy

Abstract number: TPS2690

  • Demonstrated tolerance induction and control suppression in rigorous preclinical models of type 1 diabetes
  • From ongoing experience, has shown efficacy in NOD preclinical model
    • Increasing to 3 administered doses and optimizing the dosing regimen, results at 25 weeks show proximity suppression delivering only two antigens, indicating prevention of disease caused by many self-antigens (0/5 mice)
    • Previously reported data at 25 weeks with two doses prevented or delayed disease onset (7/15 mice)
  • Established efficacy in the BDC2.5 adoptive transfer model with data supporting that repeated administration prolongs the duration of protection against disease, reverses established inflammation, which is important for the treatment of existing autoimmunity, and induces two types of regulatory T cells, resulting in protection against re-challenge
  • These results are potentially transferable beyond type 1 diabetes to multiple autoimmune diseases, including multiple sclerosis and celiac disease.

About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of drugs called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to biologically design and cultivate Red Cell Therapeutics™ which are selective, potent, ready-to-use allogeneic cell therapies for the potential treatment of multiple diseases in multiple therapeutic areas. Rubius’ initial goal is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities: potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named one of the 2021 Top Places to Work in Massachusetts by The Boston Globe, and its manufacturing site was recently named 2022 Best Places to Work in Rhode Island by Providence Business News. For more information, visit www.rubiustx.comfollow us on Twitter Where LinkedIn or like us on Facebook.

Forward-looking statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding beliefs regarding the efficacy of its Red Cell Therapeutics and the beliefs and analyzes of data from the Rubius program on type 1 diabetes, including that it is potentially translatable into several T cell-mediated autoimmune diseases. The words “may”, “will”, “could”, “should”, “should”, “expect”, “plan”, “anticipate”, “intend”, “believe”, ” estimates”, “predicts”, “project”, “potential”, “pursue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. All forward-looking statements contained in this press release are based on management’s current expectations and beliefs and are subject to a number of important risks, uncertainties and factors that may cause actual events or results to differ. differ materially from those expressed or implied by any forward-looking statement. the statements contained in this press release, including, without limitation, the risks and uncertainties associated with the development of our red blood cell therapeutic product candidates and their therapeutic potential, our ability to execute our plans and expectations, our analyzes clinical and preclinical data, including the type 1 diabetes program, and other risks identified in our filings with the United States Securities and Exchange Commission (SEC), including our annual report on Form 10- K for the fiscal year ended December 31, 2021 and subsequent filings with the SEC, including our Quarterly Report on Form 10-Q for the quarter ended March 31, 2022, and risks and uncertainties relating to the severity of a e duration of the impact of COVID-19 on our business and operations. We caution you not to place undue reliance on forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which such statements may be based, or which may affect the likelihood that actual results will differ from those set forth in forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing our views as of any subsequent date.



Lori Murray, Head of Corporate Affairs

[email protected]


Marissa Hanify, Director, Corporate Communications

[email protected]

Copyright 2022 GlobeNewswire, Inc.

Ryan H. Bowman